Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1996 May;41(5):414–416. doi: 10.1046/j.1365-2125.1996.331/1.x

Effects of exogenous female sex-steroid hormones on lymphocyte β2-adrenoceptors in normal females

K S TAN 1, L C McFARLANE 1, W J COUTIE 1, B J LIPWORTH 1
PMCID: PMC2042599  PMID: 8735683

Abstract

We have previously shown that lymphocyte β2-adrenoceptors (AR) are under cyclical control of sex-steroid hormones with greater receptor density during the luteal phase of the menstrual cycle. It has also been postulated that abnormal cyclical regulation of β2-AR might be a possible mechanism for premenstrual asthma. The effects of exogenous female sex-steroid hormones on lymphocyte β2-AR function were studied in eight normal healthy females. They were evaluated at two successive menstrual cycles, during the follicular phase (day 1–6). They were randomized to receive single oral doses of either ethinyloestradiol 50 μg or medroxyprogesterone 10 mg in a cross-over study. Lymphocyte β2-AR parameters were evaluated at baseline (t0), 24 h (t24) and 72 h (t72) after ingestion. Baseline levels of progesterone and oestradiol were comparable on both cycles. Receptor density (Bmax) increased significantly (P<0.01) from t0 after progesterone but not oestradiol at t24: a 1.39-fold geometric mean difference (95% CI 0.96–2.00) between t24vs t0. Receptor affinity (Kd) and maximal cAMP response to isoprenaline (Emax) were not altered by either treatment. These results show that exogenous progesterone but not oestradiol, given during the follicular phase, significantly increased β2-AR. This, therefore, suggests that endogenous progesterone is probably responsible for previously observed increase in Bmax during the luteal phase of the female menstrual cycle. These findings may suggest possible therapeutic strategies for modulation of β2-AR in premenstrual asthma.

Keywords: oestrogen, progesterone, β2-adrenoceptors , lymphocyte

Full Text

The Full Text of this article is available as a PDF (183.9 KB).


Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES